TB R&D Weekly Update: Podcast Interview with Dr. Yossef Av-Gay

Dr. Yossef Av-Gay

Listen to Youssef Av-Gay Podcast

Summary: Dr. Yossef Av-Gay, a professor in the Division of Infectious Diseases at the University of British Columbia, recently published a paper in the Proceedings of the National Academy of Sciences (PNAS) entitled “Mycobacterium tuberculosis protein tyrosine phosphatase (PtpA) excludes host vacuolar-H+–ATPase to inhibit phagosome acidification.” The paper provides evidence to that points to a specific protein that allows Mtb to bypass the body’s defenses. In this interview, we discuss the recently published paper, his contribution to TB drug discovery and the focus of his research.

Dr. Av-Gay’s Laboratory research is focused on the molecular pathogenesis of Mycobacterium tuberculosis in order to identify new targets for drug therapy. Using bioinformatic and pathogenomic tools, we have identified three molecular targets and we are now characterizing them for their contribution to TB pathogenesis. These targets are protein kinases of M. tuberculosis, mycothiol production and cholesterol utilization by mycobacteria.

Additional Coverage:

The stealth art of infectious agents: researchers uncover why the body can’t defend against tuberculosis

Additional TB R&D News:

2011 WGND Annual Meeting Recap now available!

IDRI Announces New VP Tuberculosis Drug Development

UK and Indian researchers unite to fight global tuberculosis epidemic

South Africa: Fight against TB yielding positive results

TB risk increases in early pregnancy, study shows

Global Tuberculosis Diagnostics Market: Growth Opportunities and Business Expansion Strategies

Discordance Among Commercially-Available Diagnostics For Latent Tuberculosis Infection

More News
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...
3 Aug 2023
The Working Group on New TB Drugs, in collaboration with the New Diagnostics Working Group, Working Group on New Vaccines, FIND, IAVI, and TB Alliance, is co-hosting a New Tools Summit at the Marriot Champs Elysée Hotel in Paris, France on Tuesday, 14 November 2023. The WGND Annual Meeting will be...
23 Aug 2022
The PAN-TB collaboration announced initial plans for a Phase 2 clinical trial evaluating two novel drug regimens to treat Tuberculosis. Sponsored by the Bill and Melinda Gates Foundation, the PAN-TB, or “Project to Accelerate New Treatments for Tuberculosis”, collaboration brings together non-...